心筋虚血の世界市場レポート 2025年

心筋虚血市場規模は、今後数年間で力強い成長が見込まれます。2029年には11億1,000万米ドルに成長し、CAGRは6.9％となります。予測期間の成長は、様々な心臓関連疾患の流行、心血管疾患に対する国民の意識の高まり、人々のライフスタイルの絶え間ない変化、糖尿病患者の増加、医療支出の増加に起因しています。予測期間の主要動向には、心筋虚血治療法の採用、より良い医療インフラ、治療オプションの進歩、デジタルヘルスソリューションの統合、心臓リハビリテーションプログラムの開始などがあります。

糖尿病の罹患率の増加が、今後数年間の心筋虚血市場の成長を促進すると予測されています。糖尿病は、血糖値を調整する膵臓からのホルモンであるインスリンを体内で生成したり、効果的に使用したりすることができなくなる代謝障害の一群です。肥満、高度肥満、運動不足、遺伝などの要因が糖尿病罹患率の上昇に寄与しています。このような糖尿病有病率の増加は、心筋虚血の発症率の増加と相関しており、糖尿病の診断、治療、管理ソリューションに対する需要を煽っています。例えば、2023年4月、英国を拠点とする糖尿病慈善団体The British Diabetic Associationの報告によると、英国では430万人が糖尿病と診断されています。2021～22年の登録データでは、2020～2021年より14万8,951件増加しています。さらに、英国では240万人以上が2型糖尿病を発症するリスクが高いです。その結果、糖尿病の罹患率の上昇が心筋虚血市場の拡大を支えています。

心筋虚血市場の主要参入企業は、炎症に対処し冠動脈疾患患者の心血管リスクを軽減するLodoco（コルヒチン）などの革新的な医薬品の開発に注力しています。Lodocoは、動脈硬化性疾患または複数の心血管危険因子が確立している成人の心筋梗塞（MI）、脳卒中、冠動脈血行再建術、心血管死亡のリスクを低下させることを特に適応としています。例えば、米国の製薬会社Agepha Pharmaは、米国食品医薬品局（FDA）の承認を受け、2023年6月にLodoco（コルヒチン）を発売しました。この承認は、心血管系の炎症を対象とした初のFDA承認治療として、重要なマイルストーンとなりました。LoDoCo2を含む臨床検査では、コルヒチン0.5mgを1日1回投与することで、プラセボと比較して心血管イベントの相対リスクが31％低下することが実証されました。ロドコは、対象となる患者の重篤な心血管イベントのリスクを軽減するために配合されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の心筋虚血PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の心筋虚血市場：成長率分析
• 世界の心筋虚血市場の実績：規模と成長、2019～2024年
• 世界の心筋虚血市場の予測：規模と成長、2024～2029年、2034年
• 世界の心筋虚血総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心筋虚血市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 症候性
• 無症候性
• 世界の心筋虚血市場：治療・診断別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 診断
• 治療
• 世界の心筋虚血市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院とクリニック
• 診断センター
• 外来手術センター
• 世界の心筋虚血市場、症候性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性心筋虚血
• 慢性的な心筋虚血
• 安定狭心症
• 不安定狭心症
• 世界の心筋虚血市場、無症候性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 無症候性心筋虚血
• 運動誘発性無症候性虚血

第7章 地域別・国別分析

• 世界の心筋虚血市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の心筋虚血市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心筋虚血市場：競合情勢
• 心筋虚血市場：企業プロファイル
  • Cardinal Health Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Bayer AG
  • Sanofi SA

第31章 その他の大手企業と革新的企業

• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Abbott Laboratories Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• Medtronic Plc
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Siemens Healthineers AG
• Merck KGaA
• GE HealthCare Technologies Inc.
• Fujifilm Holdings Corporation
• Baxter International Inc.
• Regeneron Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 心筋虚血市場、2029年：新たな機会を提供する国
• 心筋虚血市場、2029年：新たな機会を提供するセグメント
• 心筋虚血市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Myocardial ischemia, also known as cardiac ischemia, occurs when there is reduced blood flow to the heart muscle, resulting in insufficient oxygen and nutrient delivery. This condition can lead to potential damage to the heart muscle. The primary cause of myocardial ischemia is the narrowing of coronary arteries due to the buildup of plaque, which limits blood flow.

There are two main types of myocardial ischemia, symptomatic and asymptomatic. Symptomatic myocardial ischemia refers to cases where individuals experience symptoms such as chest pain or discomfort (angina) during episodes of reduced blood flow to the heart muscle. Various treatments and diagnostic approaches are utilized by different end-users including hospitals, clinics, diagnostic centers, and ambulatory surgery centers.

The myocardial ischemia market research report is one of a series of new reports from The Business Research Company that provides myocardial ischemia market statistics, including myocardial ischemia industry global market size, regional shares, competitors with a myocardial ischemia market share, detailed myocardial ischemia market segments, market trends, and opportunities, and any further data you may need to thrive in the myocardial ischemia industry. This myocardial ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myocardial ischemia market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to utilization of telemedicine and remote monitoring, development of novel reperfusion therapies for mi, increased cases of obesity, increased cases of high blood pressure, increase in cases of heart attacks.

The myocardial ischemia market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to prevalence of various heart-related diseases, growing awareness of the population about cardiovascular diseases, constantly changing lifestyles of people, rising cases of diabetes, rising healthcare expenditure. Major trends in the forecast period include adoption of myocardial ischemia treatments, better healthcare infrastructures, advancements in treatment options, integration of digital health solutions, launches of cardiac rehabilitation programs.

The increasing incidence of diabetes is anticipated to drive the growth of the myocardial ischemia market in the coming years. Diabetes is a group of metabolic disorders marked by the body's inability to produce or effectively use insulin, a hormone from the pancreas that regulates blood glucose levels. Factors such as obesity, severe obesity, insufficient physical activity, and genetics contribute to the rising rates of diabetes. This growing prevalence of diabetes correlates with a higher incidence of myocardial ischemia, thus fueling demand for diagnostic, therapeutic, and management solutions for the condition. For example, in April 2023, a report by The British Diabetic Association, a UK-based diabetes charity, indicated that 4.3 million individuals in the UK were diagnosed with diabetes. Registration data for 2021-22 showed an increase of 148,951 cases over 2020-21. Additionally, more than 2.4 million people in the UK are at high risk of developing type 2 diabetes. Consequently, the rising incidence of diabetes is supporting the expansion of the myocardial ischemia market.

Key players in the myocardial ischemia market are focusing on developing innovative medications such as Lodoco (colchicine) to address inflammation and reduce cardiovascular risk in patients with coronary artery disease. Lodoco is specifically indicated to lower the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular risk factors. For example, Agepha Pharma, a US-based pharmaceutical firm, launched Lodoco (colchicine) in June 2023, following approval by the US Food and Drug Administration (FDA). This approval marked a significant milestone as the first FDA-approved treatment targeting cardiovascular inflammation. Clinical trials, including LoDoCo2, demonstrated a 31% relative risk reduction in cardiovascular events with colchicine 0.5 mg once daily compared to placebo. Lodoco is prescribed to mitigate the risk of serious cardiovascular events in eligible patients.

In March 2024, Novo Nordisk A/S, a pharmaceutical company based in Denmark, acquired Cardior Pharmaceuticals for €1.025 billion ($1.10 billion). Novo Nordisk aims to utilize Cardior's expertise and active clinical programs to fast-track the development of CDR132L and broaden its portfolio in this essential therapeutic area. Cardior Pharmaceuticals is a biopharmaceutical company located in Germany that provides drugs for treating myocardial ischemia.

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Novo Nordisk A/S, Medtronic Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Baxter International Inc., Regeneron Pharmaceuticals Inc., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation

North America was the largest region in the myocardial ischemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myocardial ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocardial ischemia market consists of sales of statin, anticoagulants, and antiplatelet agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myocardial Ischemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myocardial ischemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myocardial ischemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myocardial ischemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Symptomatic; Asymptomatic
• 2) By Treatment And Diagnosis: Diagnosis; Treatment
• 3) By End User: Hospitals And Clinics; Diagnostic Centers; Ambulatory Surgery Centers
• Subsegments:
• 1) By Symptomatic: Acute Myocardial Ischemia; Chronic Myocardial Ischemia; Stable Angina; Unstable Angina
• 2) By Asymptomatic: Silent Myocardial Ischemia; Exercise-Induced Asymptomatic Ischemia
• Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; Roche Holding AG; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myocardial Ischemia Market Characteristics

3. Myocardial Ischemia Market Trends And Strategies

4. Myocardial Ischemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Myocardial Ischemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myocardial Ischemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myocardial Ischemia Market Growth Rate Analysis
• 5.4. Global Myocardial Ischemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myocardial Ischemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myocardial Ischemia Total Addressable Market (TAM)

6. Myocardial Ischemia Market Segmentation

• 6.1. Global Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic
• Asymptomatic
• 6.2. Global Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Treatment
• 6.3. Global Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Centres
• Ambulatory Surgery Centres
• 6.4. Global Myocardial Ischemia Market, Sub-Segmentation Of Symptomatic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Myocardial Ischemia
• Chronic Myocardial Ischemia
• Stable Angina
• Unstable Angina
• 6.5. Global Myocardial Ischemia Market, Sub-Segmentation Of Asymptomatic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Silent Myocardial Ischemia
• Exercise-Induced Asymptomatic Ischemia

7. Myocardial Ischemia Market Regional And Country Analysis

• 7.1. Global Myocardial Ischemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myocardial Ischemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myocardial Ischemia Market

• 8.1. Asia-Pacific Myocardial Ischemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myocardial Ischemia Market

• 9.1. China Myocardial Ischemia Market Overview
• 9.2. China Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myocardial Ischemia Market

• 10.1. India Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myocardial Ischemia Market

• 11.1. Japan Myocardial Ischemia Market Overview
• 11.2. Japan Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myocardial Ischemia Market

• 12.1. Australia Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myocardial Ischemia Market

• 13.1. Indonesia Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myocardial Ischemia Market

• 14.1. South Korea Myocardial Ischemia Market Overview
• 14.2. South Korea Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myocardial Ischemia Market

• 15.1. Western Europe Myocardial Ischemia Market Overview
• 15.2. Western Europe Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myocardial Ischemia Market

• 16.1. UK Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myocardial Ischemia Market

• 17.1. Germany Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myocardial Ischemia Market

• 18.1. France Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myocardial Ischemia Market

• 19.1. Italy Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myocardial Ischemia Market

• 20.1. Spain Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myocardial Ischemia Market

• 21.1. Eastern Europe Myocardial Ischemia Market Overview
• 21.2. Eastern Europe Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myocardial Ischemia Market

• 22.1. Russia Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myocardial Ischemia Market

• 23.1. North America Myocardial Ischemia Market Overview
• 23.2. North America Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myocardial Ischemia Market

• 24.1. USA Myocardial Ischemia Market Overview
• 24.2. USA Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myocardial Ischemia Market

• 25.1. Canada Myocardial Ischemia Market Overview
• 25.2. Canada Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myocardial Ischemia Market

• 26.1. South America Myocardial Ischemia Market Overview
• 26.2. South America Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myocardial Ischemia Market

• 27.1. Brazil Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myocardial Ischemia Market

• 28.1. Middle East Myocardial Ischemia Market Overview
• 28.2. Middle East Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myocardial Ischemia Market

• 29.1. Africa Myocardial Ischemia Market Overview
• 29.2. Africa Myocardial Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myocardial Ischemia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myocardial Ischemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myocardial Ischemia Market Competitive Landscape And Company Profiles

• 30.1. Myocardial Ischemia Market Competitive Landscape
• 30.2. Myocardial Ischemia Market Company Profiles
  • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Myocardial Ischemia Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca Plc
• 31.4. Abbott Laboratories Inc.
• 31.5. Eli Lilly and Company
• 31.6. Novo Nordisk A/S
• 31.7. Medtronic Plc
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Gilead Sciences Inc.
• 31.10. Siemens Healthineers AG
• 31.11. Merck KGaA
• 31.12. GE HealthCare Technologies Inc.
• 31.13. Fujifilm Holdings Corporation
• 31.14. Baxter International Inc.
• 31.15. Regeneron Pharmaceuticals Inc.

32. Global Myocardial Ischemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myocardial Ischemia Market

34. Recent Developments In The Myocardial Ischemia Market

35. Myocardial Ischemia Market High Potential Countries, Segments and Strategies

• 35.1 Myocardial Ischemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myocardial Ischemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myocardial Ischemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer